OpenAI Acquires Orchestra Bio to Accelerate AI-Driven Drug Development
OpenAI is acquiring startup Orchestra Bio to integrate it with its Rosalind life sciences platform, aiming to build AI agents that help pharmaceutical teams streamline clinical trials and drug research. With U.S. drug development currently taking over a decade, this strategic move expands OpenAI's footprint in the biotech sector alongside partnerships with industry giants like Moderna.
Source: The Decoder